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ABSTRACT
Resistant hypertension continues to pose a major
challenge to clinicians worldwide and has serious
implications for patients who are at increased risk of
cardiovascular morbidity and mortality with this
diagnosis. Pharmacological therapy for resistant
hypertension follows guidelines-based regimens although
there is surprisingly scant evidence for beneﬁcial
outcomes using additional drug treatment after three
antihypertensives have failed to achieve target blood
pressure. Recently there has been considerable interest in
the use of endoluminal renal denervation as an
interventional technique to achieve renal nerve ablation
and lower blood pressure. Although initial clinical trials
of renal denervation in patients with resistant
hypertension demonstrated encouraging ofﬁce blood
pressure reduction, a large randomised control trial
(Symplicity HTN-3) with a sham-control limb, failed to
meet its primary efﬁcacy end point. The trial however
was subject to a number of ﬂaws which must be taken
into consideration in interpreting the ﬁnal results.
Moreover a substantial body of evidence from non-
randomised smaller trials does suggest that renal
denervation may have an important role in the
management of hypertension and other disease states
characterised by overactivation of the sympathetic
nervous system. The Joint UK Societies does not
recommend the use of renal denervation for treatment of
resistant hypertension in routine clinical practice but
remains committed to supporting research activity in this
ﬁeld. A number of research strategies are identiﬁed and
much that can be improved upon to ensure better
design and conduct of future randomised studies.
SCOPE OF THE CONSENSUS STATEMENT
Resistant hypertension (RHTN) is increasingly
recognised as an important subset of uncontrolled
hypertension that carries substantial additional risk
for cardiovascular disease.1 2 Wide-ranging preva-
lence for RHTN has been reported which varies
depending on which cohorts have been examined.
However, it seems likely that the overall prevalence
is around 8–10% of all patients with hypertension
and that improved treatment of this group would
lead to considerable reduction in cardiovascular
morbidity and mortality making it a high priority
hypertension subset.3 4
Renal denervation (RDN) therapy has recently
become available as a treatment for proven RHTN,
albeit with a clinical effectiveness evidence base
limited to studies lacking blinded end points or
sham controls and mostly with small numbers of
patients.5–7 Following the announcement by
Medtronic on 9 January 2014 that the Symplicity
hypertension (HTN)-3 trial had failed to meet its
primary efﬁcacy end point, the Joint UK Societies
released an interim statement recommending a tem-
porary moratorium on RDN procedures undertaken
as a standard of care in the UK while awaiting
formal reporting and peer-reviewed publication of
the study results.8 9 This updated statement was pre-
pared following the recent publication of the
Symplicity HTN-3 study—a prospective, single-
blind, randomised, sham-controlled trial that took
place in the USA.10 In this document we consider
the RDN landscape that set the stage for the
Symplicity HTN-3 study and thereafter review the
study design and results. A number of limitations
affecting the execution of the study are now appar-
ent that provide important lessons for future studies
of RDN. Importantly, given the conﬂicting evidence
regarding the role of RDN, it is too early to use the
Symplicity HTN-3 outcome as a rationale to
abandon this novel therapeutic development. Here
we also address critical issues that must be overcome
if RDN is to progress as a therapy for RHTN or
other forms of hypertension.
SYMPLICITY HTN-3 BACKGROUND
The Symplicity HTN-3 study was conceived and
designed as a regulatory study for US approval of
RDN therapy as part of an ongoing multistage
global clinical evaluation programme for radiofre-
quency (RF) RDN initiated by Medtronic.11 The
study design allowed the investigators to address
numerous concerns that had arisen in light of the
initial studies reporting RDN as an efﬁcacious and
safe therapy for RHTN (see table 1).
Principal among these concerns were the fact
that existing studies had failed to include blinded
end points and, in particular, there was no man-
dated use of ambulatory blood pressure monitoring
(ABPM) as a means to diagnose RHTN and to
monitor response to the therapy. Furthermore,
although Symplicity HTN-2 was a randomised con-
trolled study, there was no sham control procedure
which has been recorded as important in the
proper evaluation of novel interventional proce-
dures.29 30 Despite being a novel interventional
procedure, there have been very few adverse
reports pertaining to safety of the procedure, or
long-term harmful sequelae although this may
simply reﬂect numbers of procedures performed to
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date and lack of true long-term follow-up. Case reports of renal
artery stenosis following denervation are a reminder of the
importance of long-term scrutiny for renovascular disorder fol-
lowing RDN and careful surveillance of biochemical renal
function.31 32
Other concerns over published RDN data sets included lack of
specialist management of patients with RHTN (diagnosis and
treatment, adequacy of per-protocol exclusion of secondary
HTN), and that adherence to antihypertensive medication prior to
enrolment and during the course of studies had not been
assessed.33 34 Concomitantly, hypertension specialists in a number
of European centres had also started to investigate the utility of
RDN in patients with RHTN and have reported that the number
of patients suitable for RDN (after specialist assessment and medi-
cation adjustment) would be very limited.12 35 36 Furthermore the
high responder rates of 80% or more patients exhibiting ofﬁce sys-
tolic blood pressure (SBP) reduction of >10 mmHg in earlier
trials were not replicable in a number of smaller studies which
showed less striking blood pressure (BP) lowering and substantial
heterogeneity of BP responses to RDN.37–39
SYMPLICITY HTN-3 STUDY DESIGN AND RESULTS
The Symplicity HTN-3 study was a prospective, single-blind, rando-
mised, sham-controlled trial in which patients with severe RHTN
(ofﬁce BP >160 mmHg and 24-h mean SBP >135 mmHg) were
randomly assigned in a 2:1 ratio to undergo RDN or a sham proced-
ure.11 Before randomisation, patients were intended to be receiving a
stable antihypertensive regimen involving maximally tolerated doses
of at least three drugs, including a diuretic. The primary efﬁcacy end
point was the change in ofﬁce SBP at 6 months; a secondary efﬁcacy
end point was the change in mean 24-h ambulatory SBP. In total 535
subjects were randomised of whom 364 received RDN therapy and
171 had a sham procedure. The investigators ensured adequate blind-
ing of study participants such that they were unaware whether they
had received RDN therapy or sham control (renal angiogram) and
BP assessors were blinded to the study group assignments. Although
the primary safety end point was met, with a major adverse event rate
of only 1.4% (set against an objective performance goal of <9.8%),
the study failed to meet its primary and secondary efﬁcacy end points
with no statistically signiﬁcant difference in either ofﬁce or ABPM BP
lowering between the RDN treatment and sham control arms
(ﬁgure 1). Substantial variation in BP responses was noted in both
study groups and subgroup analyses indicated that RDN therapy
might work better in patients of non-African-American ethnicity,
patients below the age of 65 years and those with preserved renal
function (estimated glomerular ﬁltration rate >60 mL/min).10
SYMPLICITY HTN-3: STUDY LIMITATIONS AND LESSONS
FOR FUTURE TRIALS OF RDN
The Symplicity HTN-3 study improved upon Symplicity
HTN-1 and HTN-2 in having a blinded secondary end point
(ABPM) and a sham control group. However, following publica-
tion of the results and presentation in international meetings, a
number of ﬁndings have come to light that indicate that there
are important lessons to be learnt about the optimal design and
execution of such studies.
Medications stability
The study design mandated each enrolled patient was on a
maximum tolerated dose or maximum Food and Drug
Administration (FDA)-approved dose of at least three antihyper-
tensive agents from different classes, for at least 2 weeks prior
Table 1 Criticisms of clinical renal denervation (RDN) data to date
Criticism Problem Potential solutions
Trial design Non-blinded design
Lack of sham control
Double-blind RDN versus sham procedure with best medical
therapy10
Patient selection and
management
No per protocol exclusion of secondary causes of hypertension Mandatory per protocol exclusion of secondary causes of
hypertension
Ensure adherence to medication
Per protocol managed lifestyle changes
Plasma/urine assay of medications/metabolites±directly observed
therapy before qualifying BP measurement
Optimal 24-h urinary sodium excretion
Non-optimised antihypertensive medications
Heterogeneity of patient suitability rates between RDN centres12 13
Guidelines-based treatment regimens with add-on spironolactone
and/or α-blockade
Referral to hypertension specialist centres
Ambulatory BP Unnecessary inclusion of pseudoresistant patients with hypertension5 6
and potential overestimation of effect on office BP
Less reduction in ambulatory BP parameters compared with office BP14
Use of ambulatory BP as entry and outcome criteria15 16
Human renal nerve
anatomy uncertain
Renovascular safety
Optimal sites for RDN yet to be defined
Incomplete characterisation of renovascular injury periprocedurally and in
the long term17
Reporting of only >60% stenoses6
No histological safety data from humans
Requirement for concurrent, periprocedural antiplatelet therapy to be
determined17
Targeting of renal nerves depends also on energy modality used18
Further use of optical coherence tomography17
Postprocedure CT angiography or magnetic resonance
angiography (MRA) at 6–12 months19
Further studies needed—may vary with energy modality used for
RDN
Predictors of response
Heterogeneity of BP
response
Only baseline, office SBP reliably predicts response across studies5 6 20
Inability to distinguish between procedural failure or non-response
Wide variation in response to RDN raises questions about role of renal
nerves in hypertension21
Autonomic function testing (where available) to be included in
clinical studies and registries5 22 23
Research into ontable assessment of efficacy of RDN24 25
Research focusing on renal nerve physiology in hypertension and
role of RDN26 27
Durability of response and
end points
6-month office BP as primary end point5 6 20 Major adverse events as primary end points
No data greater than 3 years post procedure published28 Studies and registries to extend to several years
BP, blood pressure; SBP, systolic BP.
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to enrolment. Although there was an emphasis on maintaining a
constant therapeutic regimen throughout the study, as many as
20% of patients were not on stable medications within 6 weeks
of inclusion.40 Given that attainment of full effect of diuretics
(including aldosterone antagonists) is known to take up to 8
weeks,41 it is quite possible that some of the BP changes in both
study limbs were due to late effects of the enrolment medication
regimen.
There were also substantial differences in use of aldosterone
antagonists (22.5/28.7%) and vasodilators (36.8/45%) between
the RDN/sham limbs at baseline, respectively, and a preponder-
ance of African-Americans, who are more likely to respond to
these drug classes, in the sham group (29.2% sham vs 24.8%
RDN). Indeed African-American patients demonstrated a strik-
ing SBP reduction of 17.8 mm Hg in the sham arm versus
15.5 mm Hg in the RDN limb.
Approximately 40% of patients in both arms required medica-
tions changes during the study which is unusual.40 The exact
reasons for and the disposition of the medication changes are yet
to be clariﬁed. It is noteworthy that there were eight points of
investigator/subject contact during the study with close scrutiny of
medications and BP at every point. It is possible that medication
compliance was artiﬁcially enhanced in this study (the Hawthorne
effect). Of note, although patients were asked to maintain a medi-
cation diary, adherence to antihypertensive medication was not
formally tested by directly observed therapy or by urine antihyper-
tensive drug assay in this study. It is also unfortunate that long-
term follow-up of the sham control population is already con-
founded by high cross-over to active therapy with RDN which will
negatively impact on the opportunity to determine if the sham
treatment alone had long-term implications for BP control.
RDN procedures
Attention has already focused on the large number of sites in
Symplicity HTN-3 with 111 interventionists who performed at
least one RDN procedure (34% did only a single procedure)
and with only 26 operators undertaking more than ﬁve proce-
dures.42 Although procedures were proctored (mostly by non-
clinical staff ), this does not imply that optimal denervation was
achieved.
In fact in this study the mean total number of ablation attempts
was 11.2±2.8 per patient with a mean of 9.2±2.0 per protocol
120 s ablations. In the Global Symplicity Registry (GSR),
ambulatory SBP reduced by 10.3 mm Hg (in patients with ofﬁce
BP >160 mm Hg and ambulatory BP >135 mm Hg) compared
with a reduction in ambulatory SBP of only 6.8 mm Hg in the
RDN group and 4.8 mm Hg in the sham group in Symplicity
HTN-3.43 In the GSR the mean number of bilateral ablations was
13.5±4.1, and the mean number of 120 s bilateral ablations was
11.3±3.4. In HTN-3 it was shown that with an increasing
number of RF ablations there was a greater reduction in BP; in 40
patients who underwent RDN who had more than 13 total abla-
tion attempts there was a 10.3 mm Hg reduction in ambulatory
SBP, matching the effect size in the GSR.40
In Symplicity HTN-3 only a small proportion of patients had
per-protocol RF ablation in all four quadrants of both renal
arteries.40 Disappointingly, but not surprisingly, matched cohort
analysis has indicated that delivery of ablations in all four quad-
rants of the renal artery was also associated consistently with
the greatest reductions in ofﬁce, home and ambulatory SBP
(−24.3, −9.0 and −10.3 mm Hg, respectively) but this only
applied in 19 patients out of 364 patients undergoing RDN.40
EVIDENCE THAT SUGGESTS RDN MAY BE
BENEFICIAL FOR RHTN
Data from numerous animal models have previously suggested
an important role for the renal sympathetic nervous system
(SNS) in the initiation and perpetuation of hypertension.44 In
addition, a number of human studies had demonstrated the
importance of renal nerve signalling in hypertension prior to
the publication of the Symplicity HTN-1 and HTN-2 studies.
These data have been reviewed extensively elsewhere.45 Data
from a number of smaller studies have indicated efﬁcacy for
RDN in BP lowering and improving other aspects of cardiovas-
cular function and merit consideration as follows.
Improvement in ABPM parameters
While Symplicity HTN-1 and HTN-2 provided data for efﬁcacy
and safety of RDN, the lack of ABPM in either inclusion criteria or
monitoring of BP in response to RDN has been criticised. However,
non-randomised data supporting sizeable effects of RDN on ofﬁce
and ABPM parameters have now been published in a study of 346
patients with true RHTN (n=303) and pseudoresistant HTN
(n=43).14 Early and sustained signiﬁcant reductions in ofﬁce SBP
and diastolic blood pressure (DBP) were shown at 3 months, 6
months and 12 months follow-up (ofﬁce SBP: −21.5/
Figure 1 Symplicity HTN-3 results of primary and secondary efﬁcacy end points.
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−23.7/−27.3 mmHg, ofﬁce DBP: −8.9/−9.5/−11.7 mmHg),
respectively. There was a signiﬁcant reduction with RDN in 24 h
SBP (−10.1/−10.2/−11.7 mmHg,) and diastolic blood pressure
(DBP) (−4.8/−4.9/−7.4 mmHg) at 3 months, 6 months and
12 months, respectively, as well as reduction in BP variability in
those patients with true RHTN. In patients with pseudoresistant
hypertension there was no effect on ABPM post denervation
arguing strongly against a sham effect. The GSR, presented at the
American College of Cardiology meeting (March 2014), demon-
strated a reduction of 10.3 mmHg in mean 24 h SBP in 52 patients
with treatment-RHTN taking three or more antihypertensives at
maximally tolerated doses with an ofﬁce BP >160 mmHg.43
RDN enables regression of LV hypertrophy
Reduction in LV hypertrophy and improvement in cardiac func-
tion has been demonstrated in patients with RHTN following
RDN.46 Intriguingly it has been proposed that improvement in
cardiac function and LV hypertrophy regression was independ-
ent of the magnitude of BP reduction, suggesting suppression of
neurohumoural mechanisms. It must be noted however that this
was a prospective, non-randomised, open-label unipolar RF
denervation single-centre study in a small number of patients
without sham control. More recently catheter based RDN was
demonstrated to signiﬁcantly reduce BP and LV mass and
improve EF in patients with RHTN using cardiac MRI.47 Once
again this prospective multicentre study of only 72 patients was
non-randomised and with open-label use of RDN. Importantly,
however, the magnitude of LV mass reduction seen was less than
that noted in echocardiographic studies of RDN but still com-
parable with that seen in patients with hypertension treated
with pharmacotherapy.48 Although a profound placebo effect or
greater compliance with medication might have inﬂuenced
results, to some extent the reduction in LV mass occurred inde-
pendently of BP reduction which raises the tantalising prospect
that downregulation of central cardiac (but not vasomotor) sym-
pathetic outﬂow resulting from RDN may have a direct role to
play in modulating hypertensive heart disease. The potential of
RDN as a treatment for heart failure warrants further study.
Other possible cardiovascular beneﬁts of RDN
RDN reduces heart rate in humans and may have beneﬁcial
effects in cardiac rhythm disturbance including reduction in
burden of atrial ﬁbrillation and possibly ventricular arrhythmias
as well.49 50 RDN was shown to reduce arterial stiffness and
central haemodynamics which are important prognostic markers
and this too merits further investigation.51 In two small studies,
investigators have shown that RDN improves health-related
quality of life and that this improvement was not necessarily
related to the magnitude of BP reduction.52 53
CURRENT STATE OF RDN THERAPY IN THE UK
When RDN therapy ﬁrst became available as a treatment for
RHTN, there was rapid uptake of the procedure in a number of
European Union territories where a Conformité Européene mark
had been established for various competing technologies and this
led to over 10 000 RDN procedures being undertaken world-
wide with regrettably little in the way of data capture with the
exception of several investigators who have been pioneers in the
ﬁeld. In contrast, UK uptake has been much slower with only a
handful of centres offering the procedure with responder rates
that have been markedly heterogeneous and less encouraging on
the whole.22 54 55
At one point in 2013 there were more than 60 companies
with technologies in development for RDN including ﬁrst and
second generation RF ablation catheters, ultrasound catheters,
radiotherapy catheters, cryotherapy and chemical ablation tech-
nologies.18 Following the Symplicity HTN-3 announcement a
number of companies have announced their withdrawal from
the ﬁeld of device therapy for hypertension including such large
entities as Covidien. However, several of the major devices man-
ufactures including Boston Scientiﬁc, Medtronic and St Jude
Medical, having suspended clinical trial activity within pre-
existing programmes, have announced their intention to commit
to the ﬁeld of renal sympathectomy. They are using the outputs
from Symplicity HTN-3 as an opportunity to improve design of
their future clinical trials.
THE JOINT UK SOCIETIES UPDATED PERSPECTIVE
After reviewing the evidence from the Symplicity HTN-1 and
HTN-2 studies, the Joint UK Societies produced guidance for
the use of RDN in the UK in 2011 which was summarised in an
electronically published summary consensus statement.56 The
National Institute for Health and Care Excellence subsequently
produced interim guidance for RDN that was very much in line
with our initial guidance.57 In order to protect patients from
overenthusiastic and/or inappropriate application of the proced-
ure, it was mandated that patients only be treated with RDN in
the context of multidisciplinary assessment in centres of excel-
lence with Hypertension Specialists leading on case manage-
ment. The procedure, which would be costly for the UK’s
National Health Service, was to be funded by a novel process of
‘Commissioning Through Evaluation’ designed to ensure
capture of data from all procedures in a national registry, which
would serve as a clinical and academic resource.58 Subsequently
other expert group statements have also been published from
the European Society of Hypertension, European Society of
Cardiology, Cardiovascular and Interventional Radiology
Society of Europe and an International expert Consensus
Statement all supporting the use of RDN therapy as a treatment
option for RHTN where routine measures to control BP have
failed.59–62
Following close upon the heels of the Medtronic Symplicity
HTN-3 press announcement, the Joint UK Societies produced
an interim statement calling for a temporary moratorium on UK
use of RDN therapy in anticipation of the formal publication
and presentation of the data.9 Even allowing for debate over the
interpretation of the outcomes of the Symplicity HTN-3 study,
there is still a lack of evidence to support the routine use of
RDN as a standard of care in RHTN. Hence, we recommend
the current moratorium on use of this procedure in the UK
remains in place until such time as there is Level 1 evidence in
favour of use of RDN. This view is in line with the published
evidence and is supported by a recent meta-analysis suggesting
that more large-scale randomised controlled trials in RDN are
needed before this treatment should be considered in routine
clinical practice.63
Importantly, the Joint UK Societies recognise that a substan-
tial amount of (Level II or lesser) evidence does suggest clinical
utility for RDN therapy in some patients and thus we feel that
the therapy should not be abandoned in light of the Symplicity
HTN-3 study result. Indeed, this study has continued to dissem-
inate outputs that are proving to be helpful in our learning of
how better to manage future studies of RDN. It will be essential
for device manufacturers, multidisciplinary clinicians and
researchers to collaborate closely to effectively deﬁne the path
for future studies. Key learning points from the Symplicity
HTN-3 study are summarised in table 2.
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The UK remains committed to leading, supporting and par-
ticipating in well-designed randomised controlled studies to
assess the future role of RDN in RHTN. As such the morator-
ium does not apply to clinical trials of RDN therapy. It is
important that alternative energy modalities, such as ultrasound
and chemical ablation technologies should be investigated along
with second and third generation RF catheters in appropriately
designed clinical studies with blinded end points to include
ABPM. In RHTN it is vital that careful evaluation of drug
adherence is included as a prerequisite to study entry unless
severe medication intolerance has been diagnosed. Recently
mass spectrometry drug measurement in urine has demonstrated
that many patients are not adherent with their therapy.64 The
application of similar measures in future studies will robustly
conﬁrm resistance and allow us to detect non-concordance. It is
also important that patients should not be enrolled in studies
within 8 weeks of the last change in treatment.
CRITICAL AREAS TO ADDRESS TO DETERMINE THE ROLE
OF RDN AS A THERAPY FOR RHTN
The key areas that future research in RDN must address are sum-
marised in table 1. It is remarkable that to date there is no agree-
ment on the precise anatomy of the human sympathetic nerves
and in particular the variation in their trajectories relative to the
renal arteries. In a small study of nine renal arteries harvested from
ﬁve human autopsies, it was reported that the majority of renal
nerves lie within 2 mm distance from the lumen of the renal
artery.65 However, the ﬁxation methodology used has been criti-
cised and other workers have suggested that in humans, renal
nerve distribution varies between the proximal-distal segments of
the renal artery and that the 50th and 75th centiles of distance of
nerves in the proximal segment are 2.84 and 4.67 mm, respect-
ively.66 Clearly, precise localisation of human renal nerves has
crucial implications for the application of RDN and it is important
to bear in mind that different ablation technologies (eg, RF energy,
ultrasound energy, chemical ablation) offer varying depths of renal
sympathectomy and it remains to be proven which is most effective
for human use.
Since renal nerves spiral around the artery, it is also clear that
denervation in all four quadrants of the renal artery is necessary.
This may be achieved through the use of multielectrode RF ablation
catheters and alternative means of sympathectomy including ultra-
sound and chemical ablation techniques. Ultrasound energy may
offer beneﬁt by avoiding endothelial damage and deeper
penetration of heating energy than RF. Chemical ablation techni-
ques with alcohol or guanethidine also offer potential advantage in
obviating endothelial damage although it remains unclear whether
or not dissemination of neurotoxin beyond the periadventitial layer
could be an undesired effect of such therapy.18 Determining which
energy modality and ablation therapy is best to achieve near com-
plete renal nerve ablation in the absence of damage to the renal
artery lumen (and off-target effects) remains a priority.
At present there is no marker of procedural success to inform
operators that RDN therapy has been successfully delivered
although in a number of studies it has been demonstrated that
the higher the starting SBP, the greater the response to RDN.
Preliminary data from humans indicate there could be a role for
high frequency electrical ﬁeld stimulation of the renal arteries.24
In a canine model, intralumenal renal artery electrical stimula-
tion (to activate renal nerves) was shown to increase BP, serum
catecholamines and heart rate variability, presumably through
activation of renal afferent reﬂexes; these effects were attenu-
ated following RDN.25 Currently there are no established bio-
markers of renal nerve injury (a neural ‘troponin’ would be
ideal) and early plasma markers of renal injury have not trans-
lated as trustworthy markers. Thus, interventionists remain
uninformed as to whether or not the RDN procedure they have
undertaken has achieved its intended purpose.
Ideally treatment with RDN would be limited to those patients
most likely to respond to the therapy. If a response rate is deﬁned
as a reduction in ofﬁce SBP of 10 mm Hg or more, a number of
non-randomised and non-blinded studies have indicated
responder rates in excess of 80%. However real world experience
of RDN suggests true responder rates are much more vari-
able22 39 54 55 and as such it might be ideal to phenotype patients
with hypertension to better predict responders/non-responders.
Biochemical and ethnic phenotyping is already in place in the
National Institute for Health and Care Excellence/British
Hypertension Society guideline for antihypertensive pharmaco-
therapy where patients with low renin status (black ethnicity) are
offered calcium channel blockers as ﬁrst-line therapy and those
with high renin status (Caucasian ethnicity) receive ACE/angio-
tensin receptor blocker drugs instead.67 Given the complexity of
SNS signalling and how this related to changes in vasomotor
tone, and the lack of easy applicable tests for large-scale deter-
mination of renal sympathetic overactivation, it seems unlikely
that hypertension phenotyping for SNS upregulation will evolve
into mainstream clinical practice.
Table 2 Key lessons from Symplicity HTN-3
Lesson Recommendations for the future
Hypertension specialists were not involved in most centres
Antihypertensive medications stability is critical
▸ Study entry
▸ During study
Routine use of multidisciplinary teams led by accredited hypertension specialist
Hypertension specialists should design the clinical trials in conjunction with scientists and interventionalists
Stable medication regimen for at least 8 weeks prior to study entry or use of optimised medical regimen with
washout period of 4 weeks prior to baseline if feasible and forced titration during study (does not necessarily
apply to trials of RHTN)
Maintain stable medications throughout study per protocol: strict criteria for clinically necessary medication changes
Heterogeneous study population differed from prior trials of
RDN with more African-Americans
Procedural factors
▸ Operator supervision
▸ Operator experience
Study subjects should reflect the population of resistant hypertensives—it is entirely appropriate to recruit all
ethnicities as black ethnicity is a risk factor for RHTN
Adequate proctoring for inexperienced operators
Ensure delivery of adequate ablations per artery
Ensure 4 quadrant delivery of ablation
Assume learning curve of at least 10 procedures with each RDN system
RDN, renal denervation; RHTN, Resistant Hypertension.
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One approach that merits further study is the use of non-
invasive techniques to assess baroreﬂex sensitivity (BRS) as
impaired BRS was shown to be strongly predictive of response to
RDN in patients with RHTN (although it did not predict the
magnitude of BP reduction).23 RDN was found to consistently
improve BRS in all patients studied regardless of heterogeneous
effects on BP.22 Multivariate logistic regression analysis showed
lower levels of BRS to be the strongest predictor of response to
RDN and independent of all other variables.23 Another small
study has demonstrated a novel potential role for elevated plasma
levels of angiogenic markers such as soluble fms-like tyrosine
kinase-1, intercellular cell adhesion molecule-1 and vascular cell
adhesion molecule-1 as predictors of response to RDN.68
CONCLUSION
Despite the negative results from Symplicity HTN-3, it is too
early to decide that RDN therapy is a failed treatment strategy
for RHTN. Sufﬁcient encouraging data for RDN as a means to
treat hypertension have emerged in a number of animal models
of hypertension as well as some human studies to attest to its
potential as an effective treatment for at least a subsection of
patients. Furthermore, studies have indicated that RDN may
attenuate hypertensive heart disease, decrease arrhythmia
burden and reduce arterial stiffness in addition to lowering BP.
Heterogeneity in BP responses do suggest that RDN is not a
treatment for all-comers with RHTN and that careful patient
selection will need to be augmented by better understanding of
who might best respond.
It is now the time to focus on improved study design and
meticulous execution of clinical trials with careful proctoring of
interventionalists who are unfamiliar with the procedure as there
is undoubtedly a learning curve with all novel procedures no
matter how simple they may seem from the outset. Although there
is unmet need for improved treatment strategies for patients with
RHTN, it is also quite possible that chronic RHTN, with all the
attendant circulatory maladaptation and arterial stiffening that
ensues, may not represent the best target group of patients who
would derive most beneﬁt from RDN. It remains to be proven
whether or not patients with milder forms of hypertension of
shorter duration could be the most appropriate population for this
therapy—once again high quality clinical studies are mandated
particularly as the therapy becomes less expensive in the future.
Until we have better evidence of the clinical efﬁcacy in well con-
ducted trials the Joint UK Societies recommend continuing the
moratorium on RDN in routine UK healthcare. The UK is ready
to contribute to further study the place of this therapy in the man-
agement of RHTN. With the current uncertainties, it would not
be reasonable to expect commissioners to meet the costs of treat-
ment in newly designed postmarketing studies. Industry will need
to meet the costs of industry-sponsored studies although we hope
that commissioners will support the clinical costs of National
Institute for Health Research-funded studies.
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